Influenza, Human
Conditions
Keywords
Seasonal Influenza, Trivalent Vaccine, Inactivated Vaccine
Brief summary
This is a phase I, double-blind, randomized, placebo-controlled trial with two groups of subjects to receive seasonal trivalent inactivated split virion influenza vaccine (A/H1N1; A/H3N2 and B strains) or placebo (phosphate buffered saline). A total of 60 healthy male and female adults 18 through 45 years of age will be randomized to receive vaccine (30) or placebo (30).
Detailed description
This is a phase 1, single center, double blinded, randomized, placebo-controlled study. Sixty (60) healthy male and female adults, 18 to 45 years of age, will be enrolled into the trial. Subjects will be randomized 1:1 to one of two treatment allocations: 30 to vaccine, 30 to placebo. The study will utilize a randomized block design to assure a balance of 1:1 vaccine and placebo when all subjects are enrolled. The study will be double blinded, meaning the study subjects, investigators, and the sponsor will be unaware of the treatment allocated to each subject until the clinical trial database is declared final and locked. The study should take about 5 months to complete, with each subject involved for 3 months from the day of injection. The justification for the 3 month follow up, rather than 6 month follow up is that this is an inactivated vaccine that follows very standard manufacturing practices with standard antigens. The safety of inactivated influenza vaccines is well-established. Adding length to the follow up results in delays in future testing of the vaccine for licensure.
Interventions
BIOLOGICALTrivalent Seasonal Influenza Vaccine
OTHERPlacebo
0.5 mL of phosphate buffered saline
Sponsors
National Institute of Hygiene and Epidemiology, Vietnam
World Health Organization
Department of Health and Human Services
PATH
Quintiles, Inc.
Institute of Vaccines and Medical Biologicals, Vietnam
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female adult 18 through 45 years of age at the enrollment visit. * Literate (by self-report) and willing to provide written informed consent. * Healthy, as established by the medical history, physical examination, and screening laboratory evaluations. * Capable and willing to complete Diary Cards and willing to return for all follow-up visits. * For females, willing to utilize reliable birth control measures (e.g., intrauterine device, hormonal contraception, condoms) through the Day 22 visit.
Exclusion criteria
* Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study. * Receipt of any non-study vaccine within 4 weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 22 visit. * Current or recent (within 2 weeks of enrollment) acute illness with or without fever. * Receipt of immune globulin or other blood products within 3 months prior to study enrollment or planned receipt of such products prior to the Day 22 visit. * Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, 0.5 mg per kg per day; topical steroids are allowed.) * History of asthma. * Hypersensitivity after previous administration of any vaccine. * Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein, antibiotics, and rubber (from the vaccine vial stoppers). * Acute or chronic clinically significant pulmonary, cardiovascular, hepatobiliary, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. * History of any blood or solid organ cancer. * History of thrombocytopenic purpura or known bleeding disorder. * History of seizures. * Known or suspected immunosuppressed or immunodeficient condition of any kind. * Confirmed hepatitis B virus (HBV) or hepatitis C virus (HCV) infection * Known human immunodeficiency virus (HIV) infection (self-report). * Known active tuberculosis or symptoms of active tuberculosis, regardless of cause (self-report). * History of chronic alcohol abuse and/or illegal drug use. * Pregnancy or lactation. (A negative pregnancy test will be required before administration of study product for all women of childbearing potential.) * History of Guillain-Barré Syndrome * Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives. Note: Minor out-of-range laboratory values no greater than Grade 1 will not be considered to be exclusionary at screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Immediate Adverse Events | 30-minute post-vaccination period. | Any adverse event occurring within the 30 minute post vaccination period. |
| Number and Percentage of Participants Reporting Solicited Local Reactogenicity | 7-day period (Days 1-7) post-vaccination. | Number of subjects reporting solicited local reactions (redness, swelling, pain, hardness, and tenderness) at the injection site post-vaccination with study vaccine or placebo. |
| Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | 7-day period (Days 1-7) post-vaccination | Number of subjects reporting solicted systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or placebo |
| Number and Percentage of Participants With Unsolicited Adverse Events | Within 21 days post-vaccination | Unsolicited AEs were any AEs that occurred any time after the vaccine/placebo was administered (temporally related to investigational product), whether or not deemed related to the product, and are not solicited (specifically asked of the subject). Unsolicited AEs were to be observed by the study center personnel while the subject was at the study center for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a solicited AE (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination were to be recorded as an unsolicited AE. In this study, laboratory results were considered AEs when (1) the result was judged to be clinically significant by the Principal Investigator, regardless of grade; or (2) the result is Grade 2 or higher. Note: all unsolicited AEs were mild in intensity. Please see Adverse Events section of this report for detailed information of AEs. |
| Number and Percentage of Participants With Serious Adverse Events (SAEs) | Over the entire study period (Day 91) | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens | Day 22 | Seroconversion is defined as a serum HAI titer meeting the following criteria: * pre-vaccination titer \<1:10 and a post-vaccination titer ≥ 1:40 or * pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination measured on Day 22. |
| Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens | Pre- (Day 1) and Post-vaccination (Day 22) | — |
| Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine | Day 1 and Day 22 post vaccination | A seroprotected subject was defined as a vaccinated subject who had a serum Hemagluttination Inhibition (HAI) titer \>/= 1:40. The 3 influenza strains assessed were B, H1, and H3. |
| Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | Pre- (Day 1) and post-vaccination (Day 22) | Geometric mean titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) antibodies pre- (Day 1) and post-vaccination (Day 22) for each of the 3 antigens. |
| Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies | Day 22/Day1 | Geometric mean fold rises (GMFRs) of serum hemaggluntination inhibition (HAI) antibodies post-vaccination/pre-vaccination for each of the 3 antigens |
| Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | Pre- (Day 1) and Post-vaccination (Day 22) | — |
Countries
Vietnam
Participant flow
Pre-assignment details
Sixty four (64) subjects were consented and 4 were not randomized, leaving 60 subjects for the study.
Participants by arm
| Arm | Count |
|---|---|
| Trivalent Seasonal Influenza Vaccine 0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains: B, H1N1, & H3N2 | 30 |
| Placebo 0.5 mL of Phosphate Buffered Saline | 30 |
| Total | 60 |
Baseline characteristics
| Characteristic | Trivalent Seasonal Influenza Vaccine | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 37.7 years | 37.8 years | 37.8 years |
| Race/Ethnicity, Customized Asian | 30 Participants | 30 Participants | 60 Participants |
| Race/Ethnicity, Customized Kinh | 30 participants | 30 participants | 60 participants |
| Race/Ethnicity, Customized Other | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Vietnam | 30 participants | 30 participants | 60 participants |
| Sex: Female, Male Female | 27 Participants | 21 Participants | 48 Participants |
| Sex: Female, Male Male | 3 Participants | 9 Participants | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 30 | 0 / 30 |
| other Total, other adverse events | 0 / 30 | 2 / 30 |
| serious Total, serious adverse events | 0 / 30 | 0 / 30 |
Outcome results
Primary
Number and Percentage of Participants Reporting Solicited Local Reactogenicity
Number of subjects reporting solicited local reactions (redness, swelling, pain, hardness, and tenderness) at the injection site post-vaccination with study vaccine or placebo.
Time frame: 7-day period (Days 1-7) post-vaccination.
Population: The analysis was conducted for subjects who were randomized and received a study vaccination
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Pain | None | 11 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Hardness | Mild | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Pain | Moderate | 2 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Hardness | Moderate | 1 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Tenderness | Mild | 16 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Hardness | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Pain | Mild | 17 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Swelling | Mild | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Tenderness | Moderate | 1 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Swelling | Moderate | 1 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Pain | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Swelling | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Tenderness | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Redness | Mild | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Swelling | None | 29 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Redness | Moderate | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Tenderness | None | 13 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Redness | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Redness | None | 30 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Hardness | None | 29 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Redness | None | 30 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Hardness | None | 30 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Swelling | None | 30 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Redness | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Pain | Mild | 5 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Pain | Moderate | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Pain | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Pain | None | 25 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Tenderness | Mild | 9 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Tenderness | Moderate | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Tenderness | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Tenderness | None | 21 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Hardness | Mild | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Hardness | Moderate | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Hardness | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Swelling | Mild | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Swelling | Moderate | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Swelling | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Redness | Mild | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Local Reactogenicity | Redness | Moderate | 0 Participants |
Primary
Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity
Number of subjects reporting solicted systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or placebo
Time frame: 7-day period (Days 1-7) post-vaccination
Population: The analysis was conducted for subjects who were randomized and received a study vaccination
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Joint aches | Mild | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Headache | Mild | 6 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Headache | Moderate | 1 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Headache | None | 23 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Tiredness/discomfort | Mild | 5 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Tiredness/discomfort | Moderate | 2 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Tiredness/discomfort | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Tiredness/discomfort | None | 23 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Chills | Mild | 2 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Chills | Moderate | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Chills | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Chills | None | 28 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Muscle aches | Mild | 3 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Muscle aches | Moderate | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Muscle aches | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Muscle aches | None | 27 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Vomiting | Mild | 1 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Vomiting | Moderate | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Vomiting | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Vomiting | None | 29 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Headache | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Joint aches | Moderate | 1 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Joint aches | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Joint aches | None | 29 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Nausea | Mild | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Nausea | Moderate | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Nausea | Severe | 0 Participants |
| Vaccine Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Nausea | None | 30 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Muscle aches | Moderate | 1 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Nausea | None | 27 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Joint aches | Mild | 1 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Headache | Mild | 8 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Muscle aches | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Headache | Moderate | 1 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Headache | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Nausea | Moderate | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Headache | None | 21 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Muscle aches | None | 25 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Tiredness/discomfort | Mild | 6 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Joint aches | Moderate | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Tiredness/discomfort | Moderate | 1 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Vomiting | Mild | 1 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Tiredness/discomfort | Severe | 1 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Nausea | Mild | 3 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Tiredness/discomfort | None | 22 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Vomiting | Moderate | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Chills | Mild | 3 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Joint aches | Severe | 1 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Chills | Moderate | 1 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Vomiting | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Chills | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Nausea | Severe | 0 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Chills | None | 26 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Vomiting | None | 29 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Muscle aches | Mild | 4 Participants |
| Placebo Group | Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity | Joint aches | None | 28 Participants |
Primary
Number and Percentage of Participants With Serious Adverse Events (SAEs)
Time frame: Over the entire study period (Day 91)
Population: The analysis was conducted for subjects who were randomized and received a study vaccination
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Vaccine Group | Number and Percentage of Participants With Serious Adverse Events (SAEs) | Serious Adverse Events (SAEs)--related | 0 Participants |
| Vaccine Group | Number and Percentage of Participants With Serious Adverse Events (SAEs) | SAEs--not related | 0 Participants |
| Placebo Group | Number and Percentage of Participants With Serious Adverse Events (SAEs) | Serious Adverse Events (SAEs)--related | 0 Participants |
| Placebo Group | Number and Percentage of Participants With Serious Adverse Events (SAEs) | SAEs--not related | 0 Participants |
Primary
Number and Percentage of Participants With Unsolicited Adverse Events
Unsolicited AEs were any AEs that occurred any time after the vaccine/placebo was administered (temporally related to investigational product), whether or not deemed related to the product, and are not solicited (specifically asked of the subject). Unsolicited AEs were to be observed by the study center personnel while the subject was at the study center for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a solicited AE (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination were to be recorded as an unsolicited AE. In this study, laboratory results were considered AEs when (1) the result was judged to be clinically significant by the Principal Investigator, regardless of grade; or (2) the result is Grade 2 or higher. Note: all unsolicited AEs were mild in intensity. Please see Adverse Events section of this report for detailed information of AEs.
Time frame: Within 21 days post-vaccination
Population: The analysis was conducted for subjects who were randomized and received a study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Vaccine Group | Number and Percentage of Participants With Unsolicited Adverse Events | 7 Participants |
| Placebo Group | Number and Percentage of Participants With Unsolicited Adverse Events | 7 Participants |
Primary
Number of Participants With Immediate Adverse Events
Any adverse event occurring within the 30 minute post vaccination period.
Time frame: 30-minute post-vaccination period.
Population: The analysis was conducted for subjects who were randomized and received a study vaccination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Vaccine Group | Number of Participants With Immediate Adverse Events | 0 participants |
| Placebo Group | Number of Participants With Immediate Adverse Events | 0 participants |
Secondary
Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens
Time frame: Pre- (Day 1) and Post-vaccination (Day 22)
Population: All vaccinated subjects who have valid post-vaccination immunogenicity measures with no major protocol violations
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Vaccine Group | Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens | GMFR for H1 | 47.9 fold rise |
| Vaccine Group | Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens | GMFR for B | 12.4 fold rise |
| Vaccine Group | Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens | GMFR for H3 | 17.3 fold rise |
| Placebo Group | Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens | GMFR for H1 | 1.0 fold rise |
| Placebo Group | Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens | GMFR for B | 1.0 fold rise |
| Placebo Group | Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens | GMFR for H3 | 1.0 fold rise |
Secondary
Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies
Geometric mean fold rises (GMFRs) of serum hemaggluntination inhibition (HAI) antibodies post-vaccination/pre-vaccination for each of the 3 antigens
Time frame: Day 22/Day1
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Vaccine Group | Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies | GMFR Day 22/Day 1 for H1 | 37.2 fold rise |
| Vaccine Group | Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies | GMFR Day 22/Day 1 for H3 | 16.2 fold rise |
| Vaccine Group | Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies | GMFR Day 22/Day 1 for B | 7.7 fold rise |
| Placebo Group | Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies | GMFR Day 22/Day 1 for H1 | 1 fold rise |
| Placebo Group | Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies | GMFR Day 22/Day 1 for H3 | 1.0 fold rise |
| Placebo Group | Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies | GMFR Day 22/Day 1 for B | 1.0 fold rise |
Secondary
Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens
Time frame: Pre- (Day 1) and Post-vaccination (Day 22)
Population: All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol deviations
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Vaccine Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to H1 Day 1 | 8.7 Titers |
| Vaccine Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to H1 Day 22 | 417.4 Titers |
| Vaccine Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to H3 Day 1 | 38.6 Titers |
| Vaccine Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to H3 Day 22 | 670.3 Titers |
| Vaccine Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to B Day 1 | 16.2 Titers |
| Vaccine Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to B Day 22 | 201.6 Titers |
| Placebo Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to B Day 1 | 14.6 Titers |
| Placebo Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to H1 Day 1 | 10.8 Titers |
| Placebo Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to H3 Day 22 | 39.1 Titers |
| Placebo Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to H1 Day 22 | 10.5 Titers |
| Placebo Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to B Day 22 | 14.3 Titers |
| Placebo Group | Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens | GMT to H3 Day 1 | 40.0 Titers |
Secondary
Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen
Geometric mean titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) antibodies pre- (Day 1) and post-vaccination (Day 22) for each of the 3 antigens.
Time frame: Pre- (Day 1) and post-vaccination (Day 22)
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Vaccine Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to H1 Day 1 | 10.0 Titers |
| Vaccine Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to H1 Day 22 | 371.9 Titers |
| Vaccine Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to H3 Day 1 | 39.5 Titers |
| Vaccine Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to H3 Day 22 | 640 Titers |
| Vaccine Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to B Day 1 | 8.8 Titers |
| Vaccine Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to B Day 22 | 68.1 Titers |
| Placebo Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to B Day 1 | 6.9 Titers |
| Placebo Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to H1 Day 1 | 10.6 Titers |
| Placebo Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to H3 Day 22 | 33.6 Titers |
| Placebo Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to H1 Day 22 | 10.7 Titers |
| Placebo Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to B Day 22 | 7.0 Titers |
| Placebo Group | Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen | GMT to H3 Day 1 | 35.6 Titers |
Secondary
Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine
A seroprotected subject was defined as a vaccinated subject who had a serum Hemagluttination Inhibition (HAI) titer \>/= 1:40. The 3 influenza strains assessed were B, H1, and H3.
Time frame: Day 1 and Day 22 post vaccination
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Vaccine Group | Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine | H1 | 29 Participants |
| Vaccine Group | Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine | H3 | 29 Participants |
| Vaccine Group | Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine | B | 28 Participants |
| Placebo Group | Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine | H1 | 6 Participants |
| Placebo Group | Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine | H3 | 16 Participants |
| Placebo Group | Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine | B | 0 Participants |
Secondary
Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens
Seroconversion is defined as a serum HAI titer meeting the following criteria: * pre-vaccination titer \<1:10 and a post-vaccination titer ≥ 1:40 or * pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination measured on Day 22.
Time frame: Day 22
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Vaccine Group | Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens | Seroconversion rate to H1N1 | 28 Participants |
| Vaccine Group | Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens | Seroconversion rate to H3N2 | 25 Participants |
| Vaccine Group | Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens | Seroconversion rate to B | 23 Participants |
| Placebo Group | Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens | Seroconversion rate to H1N1 | 0 Participants |
| Placebo Group | Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens | Seroconversion rate to H3N2 | 0 Participants |
| Placebo Group | Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens | Seroconversion rate to B | 0 Participants |